Genentech’s Tecentriq Should Keep Its Accelerated Approval In Breast Cancer For Now, ODAC Says

 
• By Sue Sutter
Batter up
Genentech was the first sponsor to bat at the 3-day ODAC meeting on accelerated approval indications. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers